Skip to main content

Long-term conditions: releasing capacity through optimised pathways and medicines with wider system value

15 Jun 2023
Central 7
Quality, transformation and innovation , Supporter session

Long-terms conditions (LTCs) affect more than 15 million people in England alone. As ICSs work in partnership to optimise pathways for those affected by LTCs while generating efficiency savings and capacity within already overstretched services, future service delivery will depend on understanding if earlier use of innovative medicines can be part of the solution.

This session will highlight the wider whole-system value of medicines with the speaker panel drawing on real examples of pathway redesign across the ICS network.

This session is supported by AbbVie.

Sarah Walter, Director - ICS Network - NHS Confederation
Ellen Rule, Deputy CEO / Director of Strategy & Transformation - NHS Gloucestershire ICB
Dr Julia Schofield MBE, Dermatology Clinical Lead, Outpatient Recovery and Transformation Programme - NHS England
Rachel Power, Chief Executive - Patients Association
Sarah Knight, Senior Commercial Lead - NHS England
Todd Manning, VP & General Manager, AbbVie UK - AbbVie